Business Description
Atea Pharmaceuticals Inc
NAICS : 541714
SIC : 2833
ISIN : US04683R1068
Share Class Description:
AVIR: Ordinary SharesTotal Employee Number:
55Description
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 403.8 | |||||
Equity-to-Asset | 0.88 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -12.3 | |||||
3-Year EPS without NRI Growth Rate | -11.8 | |||||
3-Year FCF Growth Rate | -3.1 | |||||
3-Year Book Growth Rate | -22.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 4.57 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 87.83 | |||||
9-Day RSI | 75.34 | |||||
14-Day RSI | 64.88 | |||||
3-1 Month Momentum % | -25.87 | |||||
6-1 Month Momentum % | 22.7 | |||||
12-1 Month Momentum % | 17.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.89 | |||||
Quick Ratio | 7.89 | |||||
Cash Ratio | 7.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 2.1 | |||||
Shareholder Yield % | 6.94 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -52.96 | |||||
ROA % | -48.25 | |||||
ROIC % | -2939.97 | |||||
3-Year ROIIC % | 3296.68 | |||||
ROC (Joel Greenblatt) % | -14082.04 | |||||
ROCE % | -58.54 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.71 | |||||
Price-to-Tangible-Book | 1.71 | |||||
EV-to-EBIT | -0.75 | |||||
EV-to-EBITDA | -0.76 | |||||
EV-to-FCF | -0.97 | |||||
| Price-to-Net-Current-Asset-Value | 1.74 | |||||
| Price-to-Net-Cash | 1.79 | |||||
Earnings Yield (Greenblatt) % | -133.33 | |||||
FCF Yield % | -37.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AVIR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Atea Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.11 | ||
| Beta | -0.2187 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.37 | ||
| Volatility % | 40.11 | ||
| 14-Day RSI | 64.88 | ||
| 14-Day ATR ($) | 0.209419 | ||
| 20-Day SMA ($) | 4.45475 | ||
| 12-1 Month Momentum % | 17.79 | ||
| 52-Week Range ($) | 2.78 - 6.45 | ||
| Shares Outstanding (Mil) | 80.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Atea Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Atea Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 16:30 | In 133 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 132 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 36 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 35 days | ||
| General meeting for 2026 | 2026-06-18 09:00 | 4.33 (+1.41%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 16:30 | 5.41 (-0.37%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 5.41 (-0.37%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 16:30 | 4.98 (+3.11%) | ||
| Annual report for 2025 | 2026-03-05 | 4.98 (+3.11%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 4.98 (+3.11%) |
Show
Entries
Atea Pharmaceuticals Inc Frequently Asked Questions
What is Atea Pharmaceuticals Inc(AVIR)'s stock price today?
The current price of AVIR is $4.98. The 52 week high of AVIR is $6.45 and 52 week low is $2.78.
When is next earnings date of Atea Pharmaceuticals Inc(AVIR)?
The next earnings date of Atea Pharmaceuticals Inc(AVIR) is 2026-08-07 Est..
Does Atea Pharmaceuticals Inc(AVIR) pay dividends? If so, how much?
Atea Pharmaceuticals Inc(AVIR) does not pay dividend.
Guru Commentaries on NAS:AVIR
No articles.
Press Release
Articles on Atea Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers